Oppenheimer Asset Management Inc. Has $18.49 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Oppenheimer Asset Management Inc. trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.6% in the third quarter, HoldingsChannel reports. The firm owned 35,957 shares of the company’s stock after selling 1,743 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Medpace were worth $18,488,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. NewEdge Advisors LLC lifted its stake in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after buying an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after acquiring an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of Medpace in the second quarter valued at approximately $296,000. Finally, IFP Advisors Inc grew its position in shares of Medpace by 223.3% in the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after purchasing an additional 134 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several recent research reports. BMO Capital Markets started coverage on Medpace in a research note on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target for the company. Mizuho set a $660.00 target price on shares of Medpace in a research report on Friday, January 9th. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. TD Cowen reiterated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Finally, Robert W. Baird set a $613.00 price objective on shares of Medpace in a report on Friday, October 24th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $491.27.

Medpace Stock Down 2.2%

MEDP stock opened at $530.35 on Tuesday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92. The business has a 50-day simple moving average of $578.30 and a 200 day simple moving average of $539.57. The company has a market cap of $14.94 billion, a PE ratio of 37.09, a price-to-earnings-growth ratio of 1.82 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same period last year, the firm earned $3.67 EPS. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the transaction, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares in the company, valued at approximately $470,787,603.56. This represents a 7.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 302,192 shares of company stock valued at $182,019,762. Company insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.